ストックスクリーナーアプリを入手
0.71
3.79%
-0.028
前日終値:
$0.738
開ける：
$0.72
24時間の取引高:
104.99K
Relative Volume:
0.39
時価総額：
$33.26M
収益：
$10.85M
当期純損益:
$-51.31M
株価収益率:
-0.9634
EPS:
-0.737
ネットキャッシュフロー:
$-40.15M
1週間 パフォーマンス:
-2.65%
1か月 パフォーマンス:
-32.38%
6か月 パフォーマンス:
-64.50%
1年 パフォーマンス:
-70.66%
1日の値動き範囲:
$0.71
$0.7649
1週間の範囲:
$0.69
$0.888
52週間の値動き範囲:
$0.69
$2.9319
InspireMD Inc. Stock (NSPR) Company Profile
Compare NSPR vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NSPR
InspireMD Inc.
|
0.71 | 33.26M | 10.85M | -51.31M | -40.15M | -0.737 |
ABT
Abbott Laboratories
|
88.41 | 153.99B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
307.80 | 118.00B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
79.34 | 101.86B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
45.29 | 67.32B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.36 | 50.30B | 6.30B | 1.07B | 1.09B | 1.8406 |
InspireMD Inc. Stock (NSPR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-02 | 開始されました | Maxim Group | Buy |
| 2016-01-07 | 開始されました | Rodman & Renshaw | Buy |
| 2015-03-13 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2013-11-26 | 開始されました | Oppenheimer | Outperform |
InspireMD Inc. (NSPR) 最新ニュース
InspireMD Inc (NSPR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
InspireMD Inc (NSPR) Institutional Confidence - TradingKey
InspireMD Inc (NSPR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
InspireMD Inc (NSPR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
InspireMD Inc (NSPR) Valuation: PE, PB & Fair Value Analysis - TradingKey
InspireMD Inc (NSPR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
InspireMD Inc (NSPR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
InspireMD Inc (NSPR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
InspireMD Inc (NSPR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
InspireMD Posts Positive CGUARDIANS II Data for CGuard Prime TCAR - Yahoo Finance
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(4) - marketscreener.com
InspireMD announces inducement grants - Medical Buyer
InspireMD Inc. (NSPR) Holds at $0.73 After Fractional Gain, Testing Key Support ZoneStock Buy Zone - newsline.com
NSPR Q1 2026 Earnings: EPS Beat Surprises on Strong Cost ManagementProfit Margin Analysis - newsline.com
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Six new InspireMD employees receive 91,161-share stock grants - Stock Titan
InspireMD, Inc. (NSPR) reports Q1 loss, tops revenue estimates - MSN
InspireMD Reports Strong 30-Day Results From CGUARDIANS II Trial - TipRanks
Inspire announces 30-day CGUARDIANS II results; 100% acute device success, no 30-day MACEs - TradingView
Stroke-prevention stent hits 100% success in 50 high-risk patients - Stock Titan
InspireMD (NSPR) reports 100% device success in TCAR trial - Stock Titan
InspireMD Announces 30-Day Results from the CGUARDIANS II Clinical Trial of the CGuard Prime 80 cm Implant for Use in TCAR Procedures - marketscreener.com
NSPR Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
NSPR Q1 2026 Earnings: EPS Surprises to the Upside Amid Limited Revenue VisibilityPost-Earnings Drift - newsline.com
InspireMD Initiates CGUARDIANS III Study for SwitchGuard Neuro Protection System in TCAR Procedures - Quiver Quantitative
InspireMD Announces First Patient Enrolled in the CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System for Use in TCAR Procedures - GlobeNewswire
NSPR Q1 2026 Earnings: EPS Surprise of 12.85% Highlights Cost Discipline Amid Pre‑Revenue Stage - newsline.com
NSPR News | INSPIREMD INC (NASDAQ:NSPR) - ChartMill
InspireMD (NSPR) holders OK 250M authorized shares, re-elect directors - Stock Titan
InspireMD NSPR Q1 2026 Earnings Transcript - The Globe and Mail
NSPR Q1 2026 Earnings: EPS Surprises to the Upside, Stock Reacts PositivelyEstimate Revision Count - thelegaladvocate.com
InspireMD director Paul Stuka buys $17,500 in shares By Investing.com - Investing.com Australia
InspireMD (NSPR) Inches Higher as Shares Approach Key Resistance at $0.97Gap and Go - thelegaladvocate.com
InspireMD director Paul Stuka buys $17,500 in shares - Investing.com
Director Paul Stuka buys 20,000 InspireMD (NSPR) shares in open-market trade - Stock Titan
InspireMD (NSPR) Gains 6% to $0.95 as Stock Approaches Critical $1.00 ResistanceHigh Conviction Picks - newsline.com
InspireMD anticipates FDA approval of original CGuard delivery system in Q3 2026 as it withdraws 2026 revenue guidance - MSN
InspireMD Inc. (NSPR) Q1 2026 Earnings: Narrower Loss Than Expected But Shares SlideEarnings Call Highlights - thelegaladvocate.com
InspireMD (NSPR) Slides 7.9% as Stock Tests Key Support Near $0.84RVOL Spike - The Legal Advocate
InspireMD (NSPR) Slides 8.4% to $0.87: Key Levels Under PressureEarnings Beat Stocks - newsline.com
InspireMD (NSPR) Q1 2026 Earnings: EPS Beat Despite Net Loss, Shares Dip 2.9%Post-Announcement Reaction - Newser
Paul Stuka to Retire from InspireMD Board, Will Not Seek Re‑election - TradingView
InspireMD (NSPR) chair Paul Stuka plans Board retirement in 2027 - Stock Titan
NSPR Q1 2026 Earnings: Loss Narrower Than Expected as InspireMD Advances Commercial PipelineProfit Growth Outlook - Newser
InspireMD CCO Shane Gleason sells $189,594 in stock By Investing.com - Investing.com Canada
InspireMD CCO Shane Gleason sells $189,594 in stock - Investing.com
InspireMD (NSPR) CCO auto-sells shares to cover RSU tax obligations - Stock Titan
InspireMD (NSPR) price target decreased by 13.33% to 4.42 - MSN
InspireMD Inc. (NSPR) 財務データ
収益
当期純利益
現金流量
EPS
0.93%
大文字化:
|
ボリューム (24 時間):